Liquidia Corp key statistics and ratios
In fiscal 2025, Liquidia Corp had return on equity of -111.1%, an operating margin of -32.5%, debt equal to 0.0% of equity and a current ratio of 2.01. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 67.9% | 76.5% | 82.1% | 83.5% | 58.0% | — | — |
| Operating margin | −580.1% | <−999% | −263.0% | −243.3% | −419.6% | −866.6% | −32.5% | 37.4% |
| Net margin | −589.5% | <−999% | −269.0% | −257.4% | −448.9% | −916.6% | −43.5% | 30.7% |
| Free-cash-flow margin | −621.1% | <−999% | −265.6% | −183.1% | −245.0% | −702.9% | −25.3% | 33.4% |
| Return on equity | −136.2% | −112.7% | −50.7% | −52.7% | −114.0% | — | −111.1% | 115.6% |
| Return on assets | −69.1% | −71.0% | −35.8% | −36.8% | −63.4% | −73.6% | −24.7% | 32.6% |
| Asset turnover | 0.12 | 0.01 | 0.13 | 0.14 | 0.14 | 0.08 | 0.57 | 1.06 |
| Current ratio | 3.34 | 5.63 | 8.36 | 11.34 | 4.85 | 4.43 | 2.01 | 2.31 |
| Debt to equity | 45.4% | 14.5% | 16.0% | 22.0% | — | 0.0% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 6.3x |
| R&D as % of revenue | 501.6% | >999% | 159.6% | 122.0% | 247.3% | 341.8% | 24.8% | 12.4% |
| SG&A as % of revenue | — | — | — | — | 255.8% | 582.8% | 99.3% | 42.7% |
| Capital spending as % of revenue | 22.9% | 101.7% | 0.8% | 3.7% | 7.4% | 35.4% | 2.7% | 3.8% |
| Free cash flow ÷ net income | — | — | — | — | — | — | — | 108.7% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 64.8% | 53.6% | 51.4% | — | — | — | — | — |
| Operating margin | −656.2% | <−999% | <−999% | −424.4% | 3.3% | 21.5% | 46.3% | 49.8% |
| Net margin | −697.6% | <−999% | <−999% | −470.5% | −6.5% | 15.8% | 39.8% | 43.5% |
| Free-cash-flow margin | −603.2% | −757.7% | −993.9% | −458.7% | −19.7% | 45.9% | 37.8% | 40.2% |
| Current ratio | 6.33 | 4.43 | 2.93 | 2.49 | 2.20 | 2.01 | 2.22 | 2.31 |
| R&D as % of revenue | 267.3% | 564.8% | 223.3% | 68.1% | 17.2% | 18.4% | 9.5% | 10.0% |
| SG&A as % of revenue | 453.7% | 726.6% | 963.5% | 439.3% | 73.7% | 52.4% | 35.3% | 33.5% |
Financial health
- Short-term assets cover short-term liabilities $438m of assets due within a year against $189m of liabilities due within a year.
- Short-term assets cover long-term liabilities $438m short-term assets against $138m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of $169m against $27m of interest.
Moat
Weak moat
How hard Liquidia's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -43.3% of total assets over 6 years.
- Pricing power 14 / 20
Gross margin has been a median 76.8%, moving by 8.5 percentage points (standard deviation) across 5 years.
- Durability 10 / 20
Operating margin has been a median -471.7%; its worst year was -715.4%.
- Cash conversion 2 / 20
Free cash flow was positive in 1 of 6 years, at a median -376.2% of revenue.
- Discipline 0 / 20
The diluted share count rose 117.4% over five years; stock-based pay has been a median 65.7% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (25 before it).
Compare with peers
- Innoviva, Inc. statistics
- Ironwood Pharmaceuticals Inc statistics
- Alvotech statistics
- Xeris Biopharma Holdings, Inc. statistics
- Evolus, Inc. statistics
Head to head: INVA vs LQDAIRWD vs LQDAALVO vs LQDA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies